These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10419001)

  • 21. Adrenal involvement in polycystic ovary syndrome.
    Gonzalez F
    Semin Reprod Endocrinol; 1997 May; 15(2):137-57. PubMed ID: 9165658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries.
    Nelson VL; Legro RS; Strauss JF; McAllister JM
    Mol Endocrinol; 1999 Jun; 13(6):946-57. PubMed ID: 10379893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic abnormalities in polycystic ovary syndrome.
    Franks S; Gharani N; McCarthy M
    Ann Endocrinol (Paris); 1999 Jul; 60(2):131-3. PubMed ID: 10456185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of Biological Markers of Body Fat Distribution and Corticosteroidogenic Enzyme Activities in Women with Polycystic Ovary Syndrome.
    de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW
    Horm Metab Res; 2019 Oct; 51(10):639-648. PubMed ID: 31578050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
    Abbott DH; Barnett DK; Bruns CM; Dumesic DA
    Hum Reprod Update; 2005; 11(4):357-74. PubMed ID: 15941725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology.
    Balen A
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):685-706. PubMed ID: 15380141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome.
    Wickenheisser JK; Nelson-Degrave VL; McAllister JM
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1720-7. PubMed ID: 15598676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The genetic basis of polycystic ovary syndrome.
    Xita N; Georgiou I; Tsatsoulis A
    Eur J Endocrinol; 2002 Dec; 147(6):717-25. PubMed ID: 12457445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome.
    Rosenfield RL; Barnes RB; Cara JF; Lucky AW
    Fertil Steril; 1990 May; 53(5):785-91. PubMed ID: 2185040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproate potentiates androgen biosynthesis in human ovarian theca cells.
    Nelson-DeGrave VL; Wickenheisser JK; Cockrell JE; Wood JR; Legro RS; Strauss JF; McAllister JM
    Endocrinology; 2004 Feb; 145(2):799-808. PubMed ID: 14576182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of adolescent polycystic ovary syndrome.
    Hardy TS; Norman RJ
    Steroids; 2013 Aug; 78(8):751-4. PubMed ID: 23624032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.
    Azziz R; Carmina E; Dewailly D; Diamanti-Kandarakis E; Escobar-Morreale HF; Futterweit W; Janssen OE; Legro RS; Norman RJ; Taylor AE; Witchel SF;
    Fertil Steril; 2009 Feb; 91(2):456-88. PubMed ID: 18950759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis.
    Chaudhary H; Patel J; Jain NK; Joshi R
    J Ovarian Res; 2021 Sep; 14(1):125. PubMed ID: 34563259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human ovarian theca cells in culture.
    Wickenheisser JK; Nelson-DeGrave VL; McAllister JM
    Trends Endocrinol Metab; 2006 Mar; 17(2):65-71. PubMed ID: 16460956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genetic basis of polycystic ovary syndrome.
    Franks S; Gharani N; Waterworth D; Batty S; White D; Williamson R; McCarthy M
    Hum Reprod; 1997 Dec; 12(12):2641-8. PubMed ID: 9455828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ovarian androgen-producing cells: a 2001 perspective.
    Magoffin DA
    Rev Endocr Metab Disord; 2002 Jan; 3(1):47-53. PubMed ID: 11883104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.